Tags : KRAS Cancer Program

Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to

Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim to get right to utilize Lupin’s LNP3794 in combination with its KRAS inhibitors for patients with gastrointestinal and lung cancers harboring KRAS mutations The focus of the agreement is to robust Boehringer’s […]Read More